Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

@article{Araki2016AllogeneicHC,
  title={Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?},
  author={Daisuke Araki and Brent L Wood and Megan K. D. Othus and Jerald P Radich and Anna B. Halpern and Yi Zhou and Marco Mielcarek and Elihu Estey and Frederick R Appelbaum and Roland B Walter},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 4},
  pages={
          329-36
        }
}
PURPOSE Patients with acute myeloid leukemia (AML) who are in morphologic complete remission are typically considered separately from patients with active disease (ie, ≥ 5% marrow blasts by morphology) in treatment algorithms for allogeneic hematopoietic cell transplantation (HCT), which implies distinct outcomes for these two groups. It is well recognized that the presence of minimal residual disease (MRD) at the time of transplantation is associated with adverse post-HCT outcome for those… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 31 times over the past 90 days. VIEW TWEETS